Primecap Management
SAGE

Primecap Management’s Sage Therapeutics SAGE Stock Holding History

Primecap Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-74,950
Closed -$1.62M – 338
2023
Q4 		$1.62M Sell
74,950
-14,900
-17% -$295K ﹤0.01% 316
2023
Q3 		$1.85M Buy
89,850
+26,250
+41% +$758K ﹤0.01% 305
2023
Q2 		$2.99M Sell
63,600
-2,800
-4% -$139K ﹤0.01% 295
2023
Q1 		$2.79M Buy
66,400
+1,800
+3% +$77.4K ﹤0.01% 295
2022
Q4 		$2.46M Sell
64,600
-13,200
-17% -$504K ﹤0.01% 293
2022
Q3 		$3.05M Hold
77,800
– – ﹤0.01% 292
2022
Q2 		$2.51M Buy
77,800
+9,000
+13% +$302K ﹤0.01% 300
2022
Q1 		$2.28M Buy
68,800
+4,700
+7% +$177K ﹤0.01% 307
2021
Q4 		$2.73M Buy
+64,100
New +$2.68M ﹤0.01% 309

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Primecap Management's SAGE Position: Q1 2024 in Review

Primecap Management sold out of Sage Therapeutics (SAGE) in Q1 2024, closing a stake of 74,950 shares — an estimated $1.62M sold.

Primecap Management first reported a position in SAGE in Q4 2021 and held it in 9 quarters. The position peaked at $3.05M in Q3 2022. 205 funds tracked by Wall St. Rank hold SAGE as of Q1 2024.

  • Primecap Management reported no remaining Sage Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Primecap Management sold 74,950 Sage Therapeutics shares in Q1 2024, an estimated $1.62M.
  • Primecap Management first reported a position in Sage Therapeutics in Q4 2021 and held it in 9 quarters.
  • Primecap Management's Sage Therapeutics position peaked at $3.05M in Q3 2022.
  • 205 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2024.

Based on Primecap Management's 13F filing for Q1 2024, filed 14 May 2024.